Alere (ALR) Misses Q2 EPS by 16c

Alere (NYSE: ALR) reported Q2 EPS of $0.42, $0.16 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $738.3 million versus the consensus estimate of $747.55 million.

Namal Nawana, Interim Chief Executive Officer and Chief Operating Officer of Alere said, "The second quarter was a period of significant transition for Alere. With the recently announced change in leadership, we are now narrowing our focus on our global leading rapid diagnostic business and pursuing opportunities with the highest potential for value creation. This new strategic direction will center on Alere's core strengths in rapid diagnostics and our focus areas of infectious and cardiometabolic disease and toxicology, which will enhance our ability to deliver more consistent and improved financial results. Alere's Board and management team are committed to determining the best allocation of resources to drive growth and shareholder value creation."

For earnings history and earnings-related data on Alere (ALR) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c
• Innovaro (INV) Misses Q2 EPS by 9c